FIELD: biochemistry.
SUBSTANCE: described is use of antibodies or fragments thereof, which specifically bind hDH4 and block the interaction between Dll4 and Notch receptor for preventing, treating or relieving diabetes mellitus type 1 in an individual.
EFFECT: invention extends range of products for treating, preventing type 1 diabetes mellitus.
18 cl, 11 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587620C2 |
| METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
| HUMAN ANTIBODIES TO DELTA-LIKE HUMAN LIGAND-4 | 2007 |
|
RU2448979C2 |
| HIGH-AFFINITY HUMAN IL-4 RECEPTOR ANTIBODIES | 2007 |
|
RU2445318C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| ANTIBODIES AGAINST HUMAN GDF8 | 2011 |
|
RU2567805C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| GDF8 HUMAN ANTIBODIES | 2011 |
|
RU2710156C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| HUMAN ANTIBODIES WITH HIGH AFFINITY TO HUMAN IL-4 RECEPTORS | 2009 |
|
RU2539774C2 |
